Table 1.
Clinicopathologic Characteristics of BRCA1/2-mutated and non-BRCA1/2-mutated Patients and Lesions.
| Characteristics |
Non-gBRCA1/2-mutated |
gBRCA1/2-mutated |
P value |
|
|---|---|---|---|---|
| Number of patients | 357 (79.5%) | 92 (20.5%) | ||
| Age at first diagnosis/year | 43.1 ± 10.3 | 40.1 ± 8.6 | 0.009 | |
| Menopause | 90 (28.2%) | 16 (19.8%) | 0.131 | |
| Bilateral∗ | 24 (6.7%) | 12 (13.0%) | 0.054 | |
| Previous BC | 28 (4.5%) | 11 (8.8%) | 0.216 | |
| Family History† | 52 (15.5%) | 41 (47.3%) | <0.001 | |
| Number of lesions | 390 (79.6%) | 100 (20.4%) | ||
| Tumor Size/mm | 25.2 ± 12.3 | 25.1 ± 10.1 | 0.986 | |
| Side (Left) | 218 (55.9%) | 48 (48.0%) | 0.157 | |
| ER status | Positive | 268 (68.7%) | 58 (58.0%) | 0.043 |
| Negative | 122 (31.3%) | 42 (42.0%) | ||
| PR status | Positive | 237 (60.8%) | 53 (53.0%) | 0.158 |
| Negative | 153 (39.2%) | 47 (47.0%) | ||
| HER2 status | Positive | 100 (25.6%) | 10 (10.0%) | 0.001 |
| Negative | 290 (74.4%) | 90 (90.0%) | ||
| Ki-67 | ≥20% | 313 (80.3%) | 96 (96.0%) | <0.001 |
| <20% | 77 (19.7%) | 4 (4.0%) | ||
| Molecular subtype | Luminal A | 52 (13.3%) | 4 (4.0%) | <0.001 |
| Luminal B1 | 166 (42.6%) | 55 (55.0%) | ||
| Luminal B2 | 67 (17.2%) | 5 (5.0%) | ||
| TNBC | 72 (18.5%) | 31 (31.0%) | ||
| HER2+ HR- | 33 (8.5%) | 5 (5.0%) | ||
BC: breast cancer; ER: oestrogen receptor; PR: progesterone receptor; HR: hormone receptor; HER2: human epidermal growth factor receptor 2; TNBC: triple-negative breast cancer.
∗
Including synchronous and metachronous breast cancer.
†
Family history of gBRCA1/2-related malignancy, including breast, ovarian, pancreatic and prostate cancer.